VANAZZI, ANNA
VANAZZI, ANNA
Universita' degli Studi di MILANO
Immune Signatures Identify Patient Subsets Deriving Long-Term Benefit From First-Line Rituximab in Follicular Lymphoma
2025 G. Lolli, A. Davini, V. Tabanelli, M. Sapienza, F. Melle, G. Motta, M. Del Corvo, A. Calleri, A. Vanazzi, P. Nierychlewska, A. Maraglino, M. Castelli, M. Quattrocchi, R. Chiarle, S. Pileri, C. Tarella, E. Derenzini
Venetoclax Plus Intensified Chemoimmunotherapy as a Bridge to Allogeneic Stem Cell Transplantation in Richter Syndrome: Report of Two Cases
2024 E. Derenzini, A. Cignetti, V. Tabanelli, D. Gottardi, E. Gerbino, A. Vanazzi, S. Sammassimo, A. Maraglino, F. Melle, G. Motta, D. Malengo, E. Omodeo Salè, L. Bonello, R. Pastano, S. Pileri, F. Carnevale Schianca, C. Tarella
Hairy cell leukemia with an atypical extranodal presentation: A clinicopathological analysis of four cases
2024 V. Sangiorgio, A. Palasciano, V. Tabanelli, E. Giné, L. Guerra, F. Pagni, A. Casiraghi, I. Casaroli, G. Frigola, L. Magnano, C. Gambacorti-Passerini, E. Derenzini, A. Vanazzi, E. Campo
High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies
2024 S. Viviani, A. Vanazzi, S. Frassoni, C. Rusconi, A. Rossi, A. Romano, C. Patti, C. Schiavotto, R. Sorasio, V. Marasco, L. Lissandrini, D. Rapezzi, D. Gottardi, F. Cocito, A. Mulè, S. Leotta, G. Gini, M. Sorio, E. Derenzini, A. Rambaldi, V. Bagnardi, C. Tarella
Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL
2023 S. Mazzara, L. Travaini, F. Botta, C. Granata, G. Motta, F. Melle, S. Fiori, V. Tabanelli, A. Vanazzi, S. Ramadan, T. Radice, S. Raimondi, G. Lo Presti, M.E. Ferrari, B.A. Jereczek-Fossa, C. Tarella, F. Ceci, S. Pileri, E. Derenzini
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade
2022 V. Tabanelli, F. Melle, G. Motta, S. Mazzara, M. Fabbri, C. Agostinelli, A. Calleri, M. Del Corvo, S. Fiori, D. Lorenzini, A. Cesano, A. Chiappella, U. Vitolo, E. Derenzini, G.K. Griffin, S.J. Rodig, A. Vanazzi, E. Sabattini, C. Tarella, M.R. Sapienza, S.A. Pileri
Italian real life experience with brentuximab vedotin : results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma
2017 C. Pellegrini, A. Broccoli, A. Pulsoni, L. Rigacci, C. Patti, G. Gini, D. Mannina, M. Tani, C. Rusconi, A. Romano, A. Vanazzi, B. Botto, A. Santoro, S. Hoaus, G.M. Rigolin, P. Musto, P. Mazza, S. Molica, P. Corradini, A. Fama, F. Gaudio, M. Merli, F. Ronconi, G. Gritti, D. Vallisa, P. Tosi, A.M. Liberati, A. Pinto, V. Pavone, F. Gherlinzoni, M.P. Bianchi, S. Volpetti, L. Trentin, M.C. Goldaniga, M. Bonfichi, A. De Renzo, C. Schiavotto, M. Spina, A.M. Carella, V. Stefoni, L. Argnani, P.L. Zinzani
Italian real life experience with brentuximab vedotin : results of a large observational study on 40 relapsed/refractory systemic anaplastic large cell lymphoma
2017 A. Broccoli, C. Pellegrini, A. Di Rocco, B. Puccini, C. Patti, G. Gini, D. Mannina, M. Tani, C..M. Rusconi, A. Romano, A. Vanazzi, B. Botto, C. Carlo Stella, S. Hohaus, P. Musto, P. Mazza, S. Molica, P. Corradini, A. Fama, F. Gaudio, M. Merli, A. Gravetti, G. Gritti, A. Arcari, P. Tosi, A.M. Liberati, A. Pinto, V. Pavone, F. Gherlinzoni, V. Naso, S. Volpetti, L. Trentin, M.C. Goldaniga, M. Bonfichi, A. De Renzo, C. Schiavotto, M. Spina, S. Storti, A.M. Carella, V. Stefoni, L. Argnani, P.L. Zinzani